doxorubicin (SA033)
/ Double Bond Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 07, 2022
Doxorubicin-Trabectedin Impresses in Leiomyosarcoma
(MedPageToday)
- "Being a phase III trial, the trial did show that there was an improvement, and a significant improvement, in progression-free survival in this metastatic leiomyosarcoma population. But it does come at a cost and the cost is the additional expected manageable toxicities, but patients don't walk away feeling as well as they do when they're on Adriamycin alone....And there's also an overall survival benefit. And so for the right patient, if you could withstand the added toxicities, it certainly would be beneficial for them."
Video
February 16, 2021
Daniel M. Geynisman, MD, on Bladder Cancer: Risk-Enabled Treatment After Neoadjuvant Chemotherapy
(THE ASCO POST)
- "Daniel M. Geynisman, MD...discusses phase II results from the RETAIN BLADDER study, which sequenced bladder tumor samples while treating patients with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy."
Video
1 to 2
Of
2
Go to page
1